Trials / Recruiting
RecruitingNCT05245500
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 336 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Detailed description
This first-in-human clinical trial will begin with an exploration of MRTX1719 dose and regimen. As potentially viable regimens are identified, Phase 1b expansion cohorts may be implemented to ensure sufficient safety experience, PK information, compare food effect and relative bioavailability between capsules and tablets, and early evidence of clinical activity are available.
Conditions
- Mesothelioma
- Non Small Cell Lung Cancer
- Malignant Peripheral Nerve Sheath Tumors
- Solid Tumor
- Pancreatic Adenocarcinoma
- Advanced Solid Tumor
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRTX1719 | MRTX1719 is a potent PRMT5-MTA inhibitor. Specified dose on specified days |
Timeline
- Start date
- 2022-06-09
- Primary completion
- 2027-12-10
- Completion
- 2027-12-10
- First posted
- 2022-02-18
- Last updated
- 2025-12-05
Locations
25 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05245500. Inclusion in this directory is not an endorsement.